Literature DB >> 23482649

Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with behçet and central nervous disease.

Concepción M Nuñez-Sotelo1, Luis A Gutiérrez-Gonzalez, Martín A Rodriguez.   

Abstract

BACKGROUND: Approximately eighty-percent of patients with neuro-Behçet have parenchyma CNS disease, probably due to small-vessel vasculitis. The most used treatment is high-dose corticosteroids followed by immunosuppressive medication but efficacy of this combination has not been proven to date.
METHODS: A 23 year-old male Hispanic patient with diagnosis of Behçet's disease, with onset at the age of 18, developed a bout of oral and genital ulcers, fever 39°C to 40°C, joint inflammation, cephalea, diplopia, convergent strabismus and drowsiness. A brain MRI has shown a large T2-weighted hyperintense signal in the right subthalamic nucleus and pontobulbar area. The symptoms remitted after treatment with oral prednisone and monthly pulses of cyclophosphamide and the patient had a complete and sustained neurological recovery up to twelve months of follow-up.
RESULTS: We present here the rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with Behçet´s disease and subacute central nervous system (CNS) disease.
CONCLUSIONS: The early institution of an aggressive scheme combining high dose corticosteroids and monthly pulse cyclophosphamide therapy in a patient with Behçet disease with CNS manifestations is critical for a rapid, complete and potentially sustained response and to prevent permanent CNS damage.

Entities:  

Keywords:  Hispanic; Neuro-Behçet; cyclophosphamide

Year:  2012        PMID: 23482649      PMCID: PMC3593288     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  23 in total

1.  Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq.

Authors:  A Al-Araji; K Sharquie; Z Al-Rawi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-05       Impact factor: 10.154

2.  Large thalamic mass due to neuro-Behcet disease.

Authors:  Heike Schmolck
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 4.  Vasculitis in Behçet's disease.

Authors:  J D O'Duffy
Journal:  Rheum Dis Clin North Am       Date:  1990-05       Impact factor: 2.670

5.  HLA class I and class II allele and haplotype distribution in the Venezuelan population.

Authors:  N J Makhatadze; M T Franco; Z Layrisse
Journal:  Hum Immunol       Date:  1997-06       Impact factor: 2.850

6.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 7.  Gastrointestinal manifestations of Behcet's disease.

Authors:  Y Bayraktar; E Ozaslan; D H Van Thiel
Journal:  J Clin Gastroenterol       Date:  2000-03       Impact factor: 3.062

Review 8.  Behçet's Disease.

Authors:  V G Kaklamani; G Vaiopoulos; P G Kaklamanis
Journal:  Semin Arthritis Rheum       Date:  1998-02       Impact factor: 5.532

9.  [Neurological manifestations in Behcet's disease. Forty observations in a cohort of 300 patients].

Authors:  C Ben Taarit; S Turki; H Ben Maïz
Journal:  J Mal Vasc       Date:  2002-04

10.  Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease.

Authors:  J D O'Duffy; D M Robertson; N P Goldstein
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

View more
  1 in total

Review 1.  Rheumatologic emergencies.

Authors:  Luis Arturo Gutiérrez-González
Journal:  Clin Rheumatol       Date:  2015-06-24       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.